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Abstract A mouse cDNA that encodes a nuclear DNA binding
protein was identified by yeast two-hybrid screening using the
activation domain 2 of the nuclear receptor coactivator TIF2 as a
bait. BLAST analysis revealed that the identified cDNA encodes
a KDWK domain and contains sequences almost identical to
three tryptic peptides of rat GMEB-1 which together with the
GMEB-2 heterodimeric partner binds to the GME/CRE
sequence (glucocorticoid modulatory element) of the tyrosine
aminotransferase (TAT) promoter. Mouse GMEB-1 is ubiqui-
tously expressed in all the tissues examined. In vitro translated
mGMEB-1 bound specifically to GME oligonucleotides, either
alone or as a heterodimer with rGMEB-2. Transient transfection
experiments with TAT promoter reporter genes suggest a
potential role for mGMEB-1 as a transcriptional regulator of
the TAT promoter.
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1. Introduction
Nuclear receptors (NRs) are ligand-regulated transcription
factors that comprise the receptors for steroid and thyroid
hormones, retinoids and vitamin D [1^4]. Hormone binding
induces a transconformation in the NR ligand binding do-
main involving the C-terminal helix H12 that encompasses
the core of the conserved activation function 2 (AF2), thereby
generating the surface for interaction with transcriptional co-
activators [3^10]. Concomitantly, the interface between core-
pressors and the hormone free receptor is destabilized. Coac-
tivators and corepressors recruit multiprotein complexes
which, through modi¢cation of the acetylation status of nu-
cleosomal histones, decondense or compact chromatin at tar-
get gene promoters [9^18]. While receptor-mediated chroma-
tin decondensation appears to be required, but may not be
su⁄cient for transcription activation [19], the ligand-depen-
dent recruitment of another complex, TRAP/DRIP/SMCC,
may mediate the e¡ect of NR activation domains on the tran-
scriptional machinery (for a review, see [20]). Bona ¢de NR
coactivators such as SRC-1, GRIP1/TIF2, and pCIP/RAC3/
ACTR/AIB1/TRAM1 contain two di¡erent transcription ac-
tivation domains, AD1 and AD2 (for recent reviews, see
[9,10]). AD1 acts through recruitment of the CREB binding
protein (CBP) or the CBP-related protein p300. In addition to
AD1, we and others have demonstrated the existence of a
CBP-independent activation domain (AD2) located in the
COOH-terminal region of, for example, TIF2 and ACTR
[14,21].
Glucocorticoid receptors are ligand-dependent transcription
factors that in£uence the transcriptional activity of cognate
target gene programs, thus regulating diverse biological pro-
cesses. The expression of the tyrosine aminotransferase (TAT)
gene is triggered by glucocorticoids and glucagon, the latter
acting via cAMP. The DNA enhancer element (glucocorticoid
response element; GRE) through which the glucocorticoid
receptor stimulates TAT gene transcription was initially iden-
ti¢ed at 32.5 kb upstream of the transcription start site
[22,23]. A 26 bp cAMP response element (CRE) and a hep-
atocyte nuclear factor-4 binding site, separated by 50 bp at
33.6 kb, determine liver-speci¢c and cAMP-dependent TAT
gene activation; this is also the site of inhibition of TAT
induction by insulin and phorbol esters via protein kinase C
[24^31]. Recently, a further activity has been ascribed to the
region harboring the TAT-CRE. In chimeric promoter report-
er assays a 21 bp oligonucleotide encompassing the CRE was
reported to cause a cell type- and density-dependent left shift
in the glucocorticoid dose^response curve at sub-saturating
concentrations. In the presence of this region, referred to as
the glucocorticoid modulatory element (GME), also a positive
transcriptional response to saturating concentrations of anti-
glucocorticoids (e.g. dexamethasone-21-mesylate) was ob-
served [32^37]. In a tandem arrangement together with a
GRE in the background of a minimal promoter, the presence
of the GME did not increase the maximum response to glu-
cocorticoid but altered the EC50 values of the corresponding
dose^response curve [33,38]. In vitro binding assays of pro-
tein^DNA interactions at the TAT-CRE/GME revealed two
speci¢c complexes which generated identical methylation in-
terference patterns. It appears that the proteins involved in the
formation of both complexes contact the same bases and bind
with comparable a⁄nities to the TAT-CRE/GME. One of
these complexes has been shown to contain the cAMP re-
sponse binding protein (CREB) [27,28]. The other corre-
sponds to a multimeric complex composed of two proteins
of 88 and 67 kDa denoted GME binding protein 1 (GMEB-
1) and GMEB-2, respectively [38]. Rat GMEB-2 (rGMEB-2)
belongs to a new family of nuclear factors that contain a
highly conserved KDWK motif. The rGMEB-1 has not
been cloned, but the amino acid sequence of three tryptic
fragments revealed that rGMEB-1 seems to be a new protein
unrelated to CREB [39].
In the present study, we report the isolation of a mouse
cDNA encoding a novel KDWK motif-containing protein,
highly homologous to rat GMEB-2 and with sequences al-
most identical to the three previously described tryptic pep-
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tides of rat GMEB-1. We present evidence that mGMEB-1 is
an ubiquitously expressed nuclear protein. In vitro translated
mGMEB-1 interacts speci¢cally with the TAT-CRE/GME se-
quence, either alone or as heterodimer with rGMEB-2. Addi-
tionally, mGMEB-1 represses glucocorticoid-induced tran-
scriptional activity from the TAT promoter depending
speci¢cally on the presence of the TAT-CRE/GME element.
Our data suggest that GMEB-1 may correspond to a novel
DNA binding transcriptional regulator belonging to a new
family of trans-acting factors.
2. Materials and methods
2.1. Two-hybrid screening
The TIF2.2 deletion mutant (amino acids 1288^1464 of TIF2; en-
coding the activation domain AD2) was cloned in phase 3P of the
DNA binding domain of LexA in pBTM116 to produce a bait fusion
protein. A mouse embryo (9.5^12.5 dpc) cDNA library in the VpASV3
phage yeast vector was used for screening [40]; ampli¢cation and
plasmid excision (cre-lox system) was done in Escherichia coli
BNN132. After plasmid excision cDNAs are expressed as VP16 acidic
activation domain fusions. Two-hybrid screening [41] was done by
sequential transformation of bait and library vectors in Saccharomy-
ces cerevisiae L40a carrying two genomically integrated reporters,
lexA-HIS3 and lexA-LacZ. After transformation, yeasts were plated
on histidine-lacking selective medium containing 30 mM 3-amino-
1,2,4-triazole (ATZ) and incubated at 30‡C until transformants ap-
peared. Transformants that grew more rapidly were restreaked in
duplicate in selective medium and tested for L-galactosidase expres-
sion. One clone (C341) was selected for further analysis. Comparison
of the C341 sequence with di¡erent databases strongly suggested that
C341 is the mouse homologue of a previously described DNA-binding
activity named GMEB-1. The full-length cDNA sequence of C341
clone was identi¢ed using a 5P RACE system (Clontech).
2.2. Plasmids
The full-length cDNA sequence of C341/mGMEB-1 was subcloned
into pSG5 [42] to obtain high levels of expression from the SV40 early
promoter. GAL-GMEB-1 and VP16-GMEB-1 were constructed by
cloning a BamHI fragment containing full-length GMEB-1 cDNA
into the BamHI site of pG4M poly II and pSG5 NVP16 LB3 vectors,
respectively. PG4M poly II contains GAL DBD preceding a poly-
linker with cloning sites for the cDNA, and stop codons in all reading
frames. pSG5 NVP16 LB3 contains a cassette expressing a nuclear
localized VP16 acidic activation domain (AAD) in the context of the
pSG5 vector. rGMEB-2 was ampli¢ed by PCR from pcDNA 3.1
(vHisA)/rGMEB-2 [39] and inserted at the BamHI site of the above
described vectors to generate GAL-GMEB-2 and VP16-GMEB-2.
BamHI fragments of mGMEB-1 and rGMEB-2 were also subcloned
into a HA-pSG5puro vector (gift from A. Benecke) to produce a
tagged protein with the hemagglutinin epitope at the amino-terminus.
HA-pSG5puro is a puromycin-modi¢ed pSG5 vector (constructed by
C. Erb) that contains a hemagglutinin epitope N-terminal to a multi-
cloning site. B-GMEB-1 and B-GMEB-2 were constructed by cloning
a BamHI fragment into the pSG5puro-BNtag vector (gift from T.
Lerouge). pSG5puro-BNtag directs synthesis of epitope (region B of
human estrogen receptor (ER))-tagged fusion proteins. Details con-
cerning the plasmid constructions, all of which were veri¢ed by se-
quencing, are available on request.
2.3. Northern blot analysis
A 437 bp PCR fragment encompassing nucleotides 117^557 of C341
was 32P-labeled using the Klenow fragment of polymerase. This probe
was hybridized to a mouse mRNA blot (MTN; Clontech) using the
ExpressHyb solution (Clontech) provided by the manufacturer.
2.4. Transient transfection
Transient transfections were performed using the calcium phos-
phate co-precipitation protocol in the presence of media with char-
coal-treated serum. Cells were incubated with plasmid DNA for 14^16
h before being induced with dexamethasone (Sigma) for 24 h. Trans-
fected cells were lysed and assayed for reporter gene activity using the
CAT immunodetection system (Boehringer Mannheim) according to
the manufacturer’s instruction. L-Galactosidase, measured as previ-
ously described [21], was used to normalize CAT measurements.
2.5. Immuno£uorescence microscopy of mGMEB-1
Immuno£uorescence was performed in Cos-1 cells growing on glass
coverslips. Cells overexpressing HA-pSG5puro-mGMEB-1 or the par-
ental control vector were ¢xed in 4% formaldehyde for 10 min and
permeabilized with PBS/0.2% Triton X-100/5% BSA for 30 min at
room temperature. The presence of GMEB-1 was revealed through
its HA epitope using the monoclonal anti-HA antibody 12ca5 diluted
1/1000 in PBS/0.2% Triton X-100/1% BSA; the antigen^antibody
complexes were revealed with Texas red-labeled anti-mouse IgG
(CY3) diluted 1/300. Nuclei were stained with 5 Wg/ml Hoechst 33258.
2.6. Electrophoretic mobility shift assay
In vitro transcription/translation to produce recombinant proteins
was done with the TNT Coupled Reticulocyte Lysate System (Prom-
ega, Madison, WI, USA) using 1 Wg of the plasmids HA-GMEB-1,
HA-GMEB-2, B-GMEB-1 and B-GMEB-2, according to the supplied
instructions.
Recombinant proteins were incubated on ice with poly(dI-dC)
(50 ng) as non-speci¢c competitor in a 20 Wl reaction containing
50 mM KCl, 20 mM HEPES (pH 7.3), 2 mM DTT, 5% glycerol,
and 0.1% Triton X-100. After overnight incubation at 4‡C, 32P-la-
beled probe was added and incubated for an additional 20 min at
25‡C. Protein^DNA complexes were separated from free probe on a
4% non-denaturing polyacrylamide gel by electrophoresis at 250 V for
2 h. The dried gels were autoradiographed for 16^24 h at 380‡C using
Kodak X-omat ¢lms. In supershift analyses, the antibody against the
hemagglutinin epitope (12ca5) or against the epitope of the estrogen
receptor B region (B10) was added to the recombinant proteins 15 min
on ice before addition of the radiolabeled probe. The GME probe
used in this study (5P-CTTCTGCGTCAGCGCCAGTAT-3P) corre-
sponds to the rat TAT promoter spanning position 33654 to
33634. GMEmut is an mutant probe (5P-CTTCTGTATGAGCGC-
CAGTAT-3P) previously described [36].
3. Results
3.1. Cloning and sequence analysis of mouse GMEB-1,
a member of the KDWK family
The yeast two-hybrid system [41] was used to isolate
cDNAs encoding mouse proteins that interact speci¢cally
with the C-terminal region of TIF2. The activation domain
AD2 of TIF2 encompassing amino acids 1287^1464 was fused
to the DBD of LexA. The resulting hybrid protein (LexA-
TIF2.2; Fig. 1A) was expressed in the yeast reporter strain
L40a which harbors HIS3 and LacZ reporter genes, both
under the control of E. coli LexA promoters, thus allowing
a double selection strategy by using auxotrophy selection in
medium lacking histidine and identi¢cation of positive clones
by L-galactosidase activity. A randomly primed mouse em-
bryo cDNA library was constructed in the yeast multicopy
expression vector pvSV3 [40], such that the polypeptides are
expressed as fusion proteins with the AAD of the VP16 pro-
tein, and subsequently introduced into L40a expressing LexA-
TIF2.2. Resulting yeast transformants containing both plas-
mids were plated on synthetic minimal medium lacking histi-
dine but containing 30 mM of ATZ. The latter compound
represses residual constitutive bait activity to overcome the
problem of false positives. Quickest growing positive trans-
formants were identi¢ed and tested for L-galactosidase activ-
ity. The corresponding mouse cDNAs were re-tested to con-
¢rm TIF2 AD2 interaction using a second two-hybrid system
based on ER(DBD) chimeras and the ERE-URA3 reporter
[43]. Among the clones identi¢ed, C341 was selected for fur-
ther characterization. As shown in Fig. 1, the presence of
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clone C341 was su⁄cient to allow yeast cells to grow on
medium lacking histidine (Fig. 1B). Activation of the LacZ
reporter gene was determined by measuring L-galactosidase
activity (Fig. 1C). When expressed alone neither LexA-
TIF2.2 nor VP16-C341 transactivated the LacZ reporter
above levels seen with the DBD or the AAD alone. In con-
trast, coexpression of the two hybrid proteins resulted in a
strong expression of the reporter gene, indicating that clone
C341 and the AD2 activation domain of TIF2 interact in
yeast. Thus, we concluded that C341 corresponds to a protein
that, through direct or indirect interactions with TIF2 AD2,
increased the transcriptional activity of the LexA-TIF2.2 fu-
sion protein on its cognate reporter gene, suggesting that
C341 acts as co-activator of TIF2 AD2 in this particular
system.
The originally isolated C341 revealed a 2.4 kb sequence
encoding a 540 amino acid peptide in frame with the acidic
activation domain of VP16. A stop codon and a poly-A signal
in the 3P untranslated sequence suggested that the 3P end of
the cDNA had been cloned, whereas the start codon was
lacking. A 5P RACE led to the identi¢cation of additional
5P sequences encompassing the start codon and 50 bp of
5P UTR. The complete nucleotide and amino acid sequences
of mGMEB-1 cDNA are presented in Fig. 2. The cDNA se-
quence predicts an open reading frame of 1689 bp corre-
sponding to a polypeptide of 562 amino acids.
A BLAST search [44] of the SwissProt and EMBL data-
bases revealed a very closely related sequence termed gluco-
corticoid modulatory element protein, GMEB-2. The search
also identi¢ed a sequence with weak homology to a number of
other peptide sequences with unknown function. Multiple se-
quence alignment of the homology regions (CLUSTALW
Fig. 1. Isolation of GMEB-1 by two-hybrid assay. A: A schematic
representation of functional domains of TIF2 as well as the Lex chi-
mera used as a bait in the yeast two-hybrid screen. bHLH, basic he-
lix-loop-helix sequence; PAS, Per^Arnt^Sim domain; CID, CBP in-
teracting domain; AD, activation domain. The VP16 AAD-tagged
mouse embryo cDNA expression library is represented below. Tran-
scription of the integrated HIS3- and LacZ-based reporter genes is
regulated by a LexA promoter in the yeast reporter strain L40a.
B: Growth of transformants coexpressing LexA-TIF2.2 chimera and
clone C341 on selective medium. Negative controls (top panel and
bottom left panel) are also shown. The growth phenotypes of the
transformants were assayed using a spot test on medium lacking
histidine but containing 30 mM ATZ. Note that expression of the
VP16-C341 chimera, but not of VP16, allows yeast cells to grow on
selective medium provided LexA-TIF2.2 is expressed. Plates were in-
cubated for 2 days and photographed. C: L-Galactosidase levels in
L40a yeast strain expressing LexA (DBD) or the LexA-TIF2.2 fu-
sion protein in the presence of VP16 or VP16-C341. The LacZ re-
porter gene is under the control of a LexA promoter.
Fig. 2. Nucleotide and deduced amino acid sequences of mouse
GMEB-1 (GenBank accession number AF210433). Box refers to the
homologous region between GMEB-1 and GMEB-2. Conserved
KDWK motif is shown in bold. Underlined sequences identify three
partially sequenced tryptic fragments described by Oshima et al.
[38].
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program) revealed the presence in C341 of a conserved motif,
previously described by Gross and McGinnis as ‘KDWK mo-
tif’ [45,46].
Rat GMEB-2 and C341 exhibit 61% sequence identity in
the region (aa 78^217) harboring the KDWK motif. rGMEB-
2 has been reported to bind to the TAT-CRE/GME as a
multimeric complex together with the 88 kDa rat GMEB-1
protein, which has been previously puri¢ed to homogeneity.
Two of three tryptic peptides of rGMEB-1 [38] are identical to
residues 123^129 and 183^195 of C341 (Fig. 2); 17 of 18
residues of the third peptide are conserved. Taken together,
the sequence similarity with rGMEB-2 and the identity with
the three tryptic fragments of rGMEB-1 suggest that the C341
protein corresponds to the mouse homologue of GMEB-1.
3.2. GMEB-1 is a ubiquitously expressed nuclear protein
Northern blot analysis of NIH3T3 cells using as probe a
sequence located in the 3P UTR of C341 showed that the
predominant GMEB-1 mRNA has a size of approximately
5 kb. A second band, with an estimated size of 2.4 kb, was
also observed when a sequence that contains the KDWK
motif was used as probe (data not shown). Examination of
various mouse tissues for GMEB-1 expression revealed that
both the 5 kb and the 2.4 kb mRNAs are expressed in all
tissues tested (Fig. 3A). In testis the 2.4 kb mRNA is the most
abundant transcript. Whether this shorter GMEB-1 RNA
represents an alternative splice variant of a single GMEB-1
gene or a RNA transcript from a related protein, e.g. GMEB-
2, is under investigation.
The intracellular localization of GMEB-1 was determined
by immuno£uorescence in Cos-1 cells transfected with a vec-
tor expressing an HA-tagged GMEB-1. Fig. 3B shows that
HA-tagged GMEB-1 is an exclusively nuclear protein.
3.3. GMEB-1 binds to regulatory elements within the tyrosine
aminotransferase promoter
Since GMEB-1 was initially identi¢ed as a member of a
multimeric complex that binds to the GME/CRE sequence
present in the promoter region of the tyrosine aminotransfer-
ase gene [38], we tested whether mGMEB-1 could directly
interact with the GME/CRE motif. In vitro produced HA-
Fig. 3. A: Expression of GMEB-1 in various mouse tissues. Mouse
Multiple Tissue Northern Blot (Clontech) was probed with a
mGMEB-1 cDNA fragment probe harboring the KDWK motif.
The blot was stripped of the probe after autoradiography and re-
probed with a L-actin cDNA probe. The position of GMEB-1 and
L-actin is indicated on the right. Numbers on the left indicate the
position of molecular weight markers. B: Cellular localization of
GMEB-1. Panel 2 shows Cos-1 cells transfected with HA-pSG5-
GMEB-1, ¢xed and processed for immuno£uorescence microscopy
using anti-hemagglutinin antibody. Panel 1 shows a Hoechst stain-
ing of the same ¢eld.
Fig. 4. A: Sequence of GME oligonucleotides used for gel retarda-
tion experiments. Mutated residues which impair CRE and GMEB
binding are indicated in boldface. The boxed sequence corresponds
to the CRE binding site in the tyrosine aminotransferase promoter.
B: Binding of GMEB-1 to GME oligonucleotide in gel shift assays.
Protein^DNA complexes were separated by non-denaturing electro-
phoresis after incubating a 32P-labeled GME oligonucleotides with
unprogrammed reticulocyte lysates or programmed reticulocyte ly-
sates (expressing HA-GMEB-1, HA-GMEB-2, B-GMEB-1, or B-
GMEB-2), as indicated at the top of the ¢gure. Supershift assays
were performed with anti-hemagglutinin (anti-HA) or anti-B epitope
antibodies. In C protein levels of [35S]methionine-labeled tagged
GMEB-1 and GMEB-2 used for the gel shift assays in B are shown
to demonstrate that the two proteins are expressed at similar levels.
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or B-tagged GMEB-1 (termed ‘HA-GMEB-1’ and ‘B-GMEB-
1’) as well as HA- and B-tagged GMEB-2 (‘HA-GMEB-2’
and ‘B-GMEB-2’) were tested in gel shift assays using 32P-
labeled GME (Fig. 4A). GMEB-1 produced a discrete band
shift, which was further retarded in the presence of anti-hem-
agglutinin antibodies. That GMEB-1 bound the GME in a
sequence-speci¢c manner was obvious from experiments using
GMEmut to which GMEB-1 was unable to bind. Note that
GMEmut corresponds to a mutated GME sequence known to
bind neither GMEBs nor CREB ([36] and data not shown).
The DNA binding activity of GMEB-1 was also tested in
the presence of an in vitro translated N-terminally tagged
GMEB-2 containing an epitope of the estrogen receptor B
region. When GMEB-1 and GMEB-2 were mixed a GME
complex was formed that migrated with a mobility distinct
from that of the corresponding GMEB-1 or GMEB-2 com-
plexes. Supershift analysis with anti-hemagglutinin and anti-B
epitope con¢rmed the presence of both proteins in the DNA
complex. However, no cooperative DNA binding was ob-
served when both proteins were present. Similar results were
obtained with HA-GMEB-2 and B-GMEB-1 (Fig. 4, lanes
11^17). Fig. 4B shows a SDS^PAGE of 35S-labeled in vitro
translated proteins to con¢rm that similar levels of proteins
were used in those gel shift assays.
3.4. GMEB-1 interacts with GMEB2
To examine the intrinsic transactivation activity as well as
the homo- and heterodimerization properties of GMEB-1, the
full-length cDNAs of GMEB-1 and GMEB-2 were fused to
either the GAL-4 DNA binding domain or to the VP16 acti-
vation domain. In Cos-1 cells none of the GAL-GMEB fusion
proteins was able to transactivate a cognate reporter gene as
no signi¢cant di¡erence was seen between the GAL DBD and
the GAL-GMEB-1 or GAL-GMEB-2 (Fig. 5A). In contrast,
transactivators such as the ER AF2 in the presence of estra-
diol or the TIF2 ADs, which were used as positive controls
linked to the GAL DBD, strongly activated transcription
from the same promoter demonstrating the presence of trans-
activation functions in these proteins (Fig. 5A).
A mammalian two-hybrid assay was used to examine the
Fig. 5. Activity and interactions of GMEBs. Activity of GMEB chimeras in mammalian one- (A) and two-hybrid (B) assays. Cos-1 cells were
co-transfected with 1 Wg of the (17m)5-TATA CAT reporter gene and 0.2 Wg of the GAL and VP16 chimeras as indicated. Each bar represents
the mean value obtained from at least three di¡erent experiments, standard deviations are indicated.
Fig. 6. E¡ect of GMEB-1 and GMEB-2 overexpression at increasing concentrations of dexamethasone (Dex). Reporter plasmids were trans-
fected into HepG2 cells and induced with the indicated concentrations of Dex in the presence or absence of 1 Wg expression vector for the
GMEBs as indicated. After 24 h cells were harvested and the CAT activities in cell lysates were determined as described in Section 2. Each
point represents the mean of the fold induction obtained from triplicate experiments.
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possible in vivo interaction between GMEB-1 and GMEB-2.
When GMEB-1 and GMEB-2 chimeras were cotransfected
with a cognate GAL-4 reporter gene a highly increased trans-
activation was observed (Fig. 5B). These results indicate the
ability of these proteins to heterodimerize and thus are in
keeping with the above DNA binding results. Note that
GMEB-2 also has a signi¢cant ability to homodimerize while
GMEB-1 homodimerizes weakly, if at all.
3.5. GMEB-1 represses transcription from the tyrosine
aminotransferase gene promoter
As the GME/CRE sequence of the TAT promoter has pre-
viously been described as a cis-acting element that causes a
left shift in the dose^response curve of the TAT gene pro-
moter to sub-saturating concentrations of glucocorticoids
[32,34,35,37,38], we investigated the potential e¡ect of
GMEBs on the transactivation of chimeric TAT promoter
reporter genes comprising the GME linked to the chloram-
phenicol acetyltransferase reporter gene [27]. As shown in Fig.
6A we analyzed the e¡ect of GMEB-1 and GMEB-2 over-
expression on the dose^response curve of the TAT promoter
to dexamethasone. In all cases, overexpression of GMEBs
produced a repression of both the basal and the dexametha-
sone-induced transcription of the TAT gene promoter; this
repression was more pronounced in the presence of GMEB-
2 than in the presence of GMEB-1.
To further examine the contribution of the GME/CRE se-
quence to GMEB-1-modulated transactivation, we studied the
e¡ect of the overexpression of GMEB-1 on a promoter re-
porter gene in which the GME/CRE sequence was mutated
[27]. Interestingly, GMEB-1 did not a¡ect TAT transcription
at any concentration of dexamethasone tested. By contrast, a
repressive e¡ect was observed on the basal level of transcrip-
tion as it was seen on the wild-type promoter. On the other
hand, overexpression of GMEB-2 repressed TAT promoter
transcription in a CRE/GME-independent manner at all the
concentrations tested. Additionally, overexpression of both
proteins had the same repressive e¡ect as overexpression of
GMEB-2 alone. These results suggest that GMEB-1 repres-
sion of dexamethasone-induced TAT activity appears to be
dependent on DNA binding to the GME/CRE sequence.
4. Discussion
4.1. GMEB-1 acts as a TIF2 AD2 cofactor in yeast but not in
mammalian cells
The two TIF2 activation functions, AD1 and AD2, appar-
ently operate through di¡erent transcriptional activation cas-
cades. While the TIF2 AD1 activation domain could not be
separated by mutational analysis from the TIF2 domain
which interacts in vitro and in vivo with a region of the
CBP surface, neither this region nor the full-length CBP in-
teracted with the TIF2 AD2 [21]. In an attempt to de¢ne the
mechanism mediating TIF2 AD2 activity, we have identi¢ed a
new mouse cDNA and have initiated the characterization of
the encoded protein. Interestingly, a yeast two-hybrid analysis
shows a strong functional interaction between the TIF2 AD2
activation domain and GMEB-1 in yeast when they were
tested in a two-hybrid system. However, this interaction has
not been observed using a similar approach in a mammalian
system. Additionally, no physical interaction was found in
vitro when these two proteins were tested in GST pull-down
experiments (data not shown). Apparently, these observations
suggest that yeast cells contains some factor(s) that establish a
link between GMEB-1 and TIF2 AD2. It is possible that
homologous factors exist in mammalian cells but are ex-
pressed in a cell-speci¢c manner. However, we can also not
exclude the possibility that speci¢c post-transcriptional mod-
i¢cations are required for this interaction. Such modi¢cations
may occur in yeast due to the conservation of the appropriate
enzymatic machinery, but may be only cell-speci¢cally active
in certain mammalian cells.
4.2. GMEB-1 belongs to an emerging family of polypeptides
which share a KDWK domain
A sequence homology search with C341 revealed the highest
homology with the rat GMEB-2 peptide sequence [39]. More-
over, clone C341 encodes three tryptic fragments of the rat
GMEB-1, the dimerization partner of GMEB-2, thus strongly
suggesting that clone C341 is mouse GMEB-1. GMEB-1 and
GMEB-2 possess little homology with other known nuclear
proteins. The only signi¢cant homology with other known
proteins was found in an 80^90 amino acid domain described
previously as the KDWK domain [46]. This domain appears
in a number of nuclear proteins from di¡erent species, such as
human, rat, Drosophila and Caenorhabditis elegans. Signi¢-
cantly, no matches were found in the genomes of prokaryotes
or eukaryotic unicellular organisms, suggesting that this gene
family is a feature of metazoans. The role played by the
KDWK domain is unknown. The best characterized
KDWK proteins are the Drosophila DEAF-1 protein [46]
and NUDR (for ‘nuclear DEAF-1 related’) [47]. Drosophila
DEAF-1 is a DNA binding protein that has been shown to be
an important cofactor in Deformed (Dfd) gene expression
during embryonic development. NUDR is a nuclear regula-
tory factor identi¢ed by a⁄nity binding to a synthetic retinoic
acid response element. The sequence and functional similar-
ities between NUDR and DEAF-1 suggest that NUDR may
also act as a cofactor to regulate the transcription of genes
during fetal development or di¡erentiation of testicular cells
[47]. Others proteins with a homologous KDWK domain in-
clude mammalian Suppressin [48], a protein highly related to
NUDR, the nuclear body proteins SP100, Lysp100 and SP140
[49,50], two interferon-induced nuclear phosphoproteins of
unknown function [51], and several uncharacterized C. elegans
gene products [52]. Signi¢cantly, most of these proteins have
been reported to exhibit aberrant migration rates when ana-
lyzed by SDS^PAGE. The calculated molecular mass of
GMEB-1 is 65 kDa but the protein produced by in vitro tran-
scription/translation migrates with an apparent molecular
mass of 85 kDa (data not shown). Di¡erences between the
electrophoretic mobility of proteins and their actual molecular
mass can be attributed either to post-translational modi¢ca-
tions of the translated products or to speci¢c amino acid
regions that may bind SDS in an anomalous fashion, prob-
ably the KDWK domain may be responsible for this anomaly
in this protein family [53].
4.3. Does GMEB-1 function as a transcriptional regulator in
the tyrosine aminotransferase promoter?
Zeng et al. [39] have shown that the rat homologues of
GMEB-1 and GMEB-2 interact with each other and bind
the GME sequence present in the tyrosine aminotransferase
gene promoter as a heterodimeric complex. In line with this,
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our experimental data support that GMEB-1 is a nuclear
protein with some DNA binding properties. In vitro,
GMEB-1 alone or as heterodimer with GMEB-2 binds to
the GME sequence in a speci¢c manner, as mutation of three
residues in this element abolishes both GMEB-1 and GMEB-
1/GMEB-2 binding. However, we did not ¢nd any structural
homology with known DNA binding motifs (e.g. zinc ¢ngers),
despite some cysteine clustering in the N-terminal part of
GMEB-1 [54,55]. Both GMEB polypeptides are acidic, with
a particularly high concentration of acidic residues in their
carboxy-terminal regions, which are also rich in proline, ser-
ine, and threonine, suggesting that these could be transactiva-
tion domains. However, we were unable to ¢nd conditions, if
they exist, in which recruitment of GMEBs to a promoter
would result in transcription activation of the corresponding
gene and we were thus unable to detect the presence of an
autonomous transcription activation domain in GMEBs.
However, we cannot exclude that additional signalling path-
ways may be required to confer transcriptional activation po-
tential on the GMEBs. In this context, we note the presence of
putative phosphorylation sites for several serine/threonine ki-
nases in these proteins. The fact that GMEB-1 shares certain
properties with conventional transcriptional regulators (i.e.
heterodimerization with related proteins and speci¢c DNA
binding) but does not show an intrinsic activation domain
under conditions where other activators do, suggests that (i)
GMEB-1 can act as a DNA binding factor without a real
activation function, i.e. GMEB-1 could be a modulator of
the DNA binding activity of other transcriptional factors or
it could harbor an activity required for the modi¢cation of
di¡erent proteins involved in transcription, or (ii) the GMEB-
1 transactivation function acts in a cell-speci¢c manner and
we have not tested the proper cells. This latter hypothesis
would be in keeping with the yeast results and would point
to an evolutionarily conserved pathway for GMEB activation.
As mentioned before a major role attributed to GMEBs is
to modulate glucocorticoid induction of the TAT gene as a
function of cell type and density. In view of this general as-
sumption we expected that overexpression of GMEBs could
promote a left shift in the dose^response curve for dexame-
thasone induction of the tyrosine aminotransferase gene pro-
moter, as described previously [37]. However, in our experi-
mental setting GMEB overexpression repressed TAT
promoter activity at all concentrations of dexamethasone
tested. The same e¡ect was seen for non-induced transcrip-
tion. It is possible that overexpression of GMEBs can cause
the sequestration of some limiting factors required for TAT
gene transcription in HepG2 cells, resulting in squelching phe-
nomena [56^59]. This possibility is supported by the observa-
tion that GMEB-2 inhibited TAT promoter activity even in
pTAT-CREmut, suggesting a DNA binding-independent ac-
tion of GMEB-2.
While the analysis of mGMEB-1 was carried out, Theriault
et al. isolated the human homologue of GMEB-1 using the
heat shock protein 27 (HSP27) as bait in a yeast two-hybrid
assay [60]. In contrast to the present study, Theriault et al.
could monitor direct HSP27-GMEB-1 interaction. Under-
standing how GMEB-1 can interact with two apparently dis-
tinct baits will require identi¢cation of the HSP27-GMEB-1
interaction surface and the de¢nition of the interaction mode
of TIF2 and GMEB-1. Additionally, cloning of GMEB-1 as a
parvovirus initiation factor (PIF), essential for viral replica-
tion, was reported while this article was under review [61]. The
DNA binding-based cloning of GMEB-1/PIF can be under-
stood from the similarity of PIF and ATF/CRE binding sites
(see [61] for details). However, it remains to be studied
whether GMEB-1/PIF serves a dual function or whether this
DNA binding factor is simply ‘misused’ by the viral replica-
tion machinery.
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